Lung Cancer Awareness Month: American Lung Association Celebrates Progress; Focuses Work on Ending Lung Cancer

This November, during Lung Cancer Awareness Month, the American Lung Association’s LUNG FORCE initiative is driving critical awareness about lung cancer. LUNG FORCE is working to end this devastating disease through the release of the annual “State of Lung Cancer” report, promotion of lifesaving lung cancer screening, and efforts to fund groundbreaking research.

“Lung cancer is a disease that can impact anyone, and no one deserves it,” said Harold Wimmer, President and CEO of the American Lung Association. “While it remains the leading cause of cancer deaths in the U.S., we have seen incredible progress. The survival rate has increased by 44% in the past decade, and awareness is growing. But we need to do more to save lives.”

The American Lung Association’s seventh annual “State of Lung Cancer” report, releasing on November 19, will provide an in-depth analysis of how lung cancer affects communities across the nation. It examines key factors such as new case rates, survival rates, early diagnosis, surgical treatment, access to care, and biomarker testing, and presents opportunities for states and the federal government to take action to help end lung cancer.

The Importance of Early Detection through Lung Cancer Screening
Lung cancer screening is a critical tool in detecting the disease early, which is when it is most treatable. If lung cancer is caught before it spreads to other parts of the body, the chance of surviving five years or more increases to 64%. Individuals aged 50 to 80, who currently smoke or have quit within the last 15 years may be eligible for screening. People can see if they are eligible for lung cancer screening by taking a two-minute quiz at SavedByTheScan.org.

Advancements in Biomarker Testing and Treatment
Biomarker testing has transformed how lung cancer is treated. By identifying the DNA and protein makeup of tumors, physicians can match patients with targeted therapies that can slow or even shrink tumors. Testing for the PD-L1 protein, in particular, helps determine whether immunotherapy may be an effective treatment option.

“Since 2014, more than 60 new lung cancer therapies have been approved by the FDA, offering renewed hope for those living with lung cancer,” added Wimmer. “These innovations underscore the importance of continued research.”

2024 marks a decade since LUNG FORCE was established as the first national movement to unite those impacted by lung cancer and their caregivers. To learn more and get involved, visit LUNGFORCE.org.